About ReAlta Life Sciences
ReAlta Life Sciences is a Healthcare company based in Norfolk (United States) founded in 2018. Therapeutic drugs for acute inflammatory and rare diseases are developed. It operates on a HealthTech model. ReAlta Life Sciences has raised $121.5 million across 5 funding rounds from investors including Marathon Pharma. The company has 19 employees. Its chief executive, as recorded, is Ulrich Thienel. ReAlta Life Sciences offers products and services including RLS-0071 (pegtarazimod) and EPICC Platform. Its focus areas include Biotechnology and Rare Disease Treatments. Its legal entity is ReAlta Life Sciences, Inc. Its competitors include Moderna, BridgeBio and Spark Therapeutics; 3 of its 3 listed competitors have raised funding.
Company details
ReAlta Life Sciences, a clinical-stage company, is dedicated to addressing rare diseases through innovative drug development. The company has created a novel class of drugs utilizing the EPICC platform, which offers dual-targeting therapeutic capabilities to rebalance complement and inflammatory processes. Research and development initiatives are centered on acute inflammatory and rare diseases such as Hypoxic Ischemic Encephalopathy, Acute Exacerbations of COPD, Graft-versus-Host Disease, and Platelet Refractoriness. Solutions are developed to modify disease progression by moderating robust components of humoral and cellular inflammatory responses across various therapeutic areas.
- Headquarters Norfolk, United States
- Employees 19
- SectorsHealthcare
- Email••••••••
- Phone•••• ••••
- Website realtalifesciences.com
- Social LinkedIn X Facebook Instagram
- Legal Name Realta Life Sciences, Inc.
- Total Equity Funding$121.5M (USD)
in 5 rounds
- Latest Funding Round$40M (USD), Series C
Apr 2026
- Investors
- Employee Count19
Products & Services of ReAlta Life Sciences
ReAlta Life Sciences offers a comprehensive portfolio of products and services, including RLS-0071 (pegtarazimod) and EPICC Platform.
Drug developed for rare inflammatory disease treatment purposes.
Platform used for dual-targeting inflammatory response moderation.
Funding Insights of ReAlta Life Sciences
ReAlta Life Sciences has successfully raised a total of $121.5M across 5 strategic funding rounds. The most recent funding activity was a Series C round of $40 million completed in April 2026. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $121.5M
- Total Rounds 5
- Last Round Series C — $40M
- First Round $14M
(Apr 2020)
- Investors Count 1
All 5 funding rounds of ReAlta Life Sciences with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Apr 2026 | $40M | Series C | – | – | – |
| Dec 2024 | $25M | Series B | – | – | – |
| Sep 2023 | $22.5M | Series B | – | – | – |
| Apr 2021 | $20M | Series A | – | Marathon Pharma | – |
| Apr 2020 | $14M | Series A | – | Marathon Pharma | – |
1 investors in total: 1 institutional.
Investors in ReAlta Life Sciences
ReAlta Life Sciences has secured backing from 1 investor, including institutional investors. Prominent investors backing the company include Marathon Pharma.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
New treatments for rare neurological and movement disorders are developed. | 2012 | marathonpharma.com | Northbrook, United States |
Investor details for ReAlta Life Sciences
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of ReAlta Life Sciences
20 people are tracked at ReAlta Life Sciences (7 in leadership, 9 in board & advisors, 4 in team); the tracked headcount is 19.
| Name | Role | Group |
|---|---|---|
Ulrich Thienel | CEO | Leadership |
Neel K Krishna | Chief Scientific Officer | Leadership |
Dawn Buchanan | Vice President, Head Of Clinical Operations | Leadership |
John S. Rickman | Chief Financial Officer | Leadership |
Kenji M. Cunnion | Chief Medical Officer & Director | Leadership |
Linda Dell | VP, Program Leader | Leadership |
Destrey Roberson | Vice President Clinical Operations | Leadership |
Terrie Inder | Scientific Advisor | Board & advisors |
Barry Strasnick | Director | Board & advisors |
Samuel Massoni | Scientific Advisor | Board & advisors |
Edward A. Heidt Jr. | Chairman | Board & advisors |
Christine Neikirk | Director | Board & advisors |
Jonathan Zalevsky | Director | Board & advisors |
Richard Furie | Scientific Advisor | Board & advisors |
Nathalie Maitre | Scientific Advisor | Board & advisors |
Jane Salmon | Scientific Advisor | Board & advisors |
Alana Sampson | Research Associate II | Team |
Jessica Goss | Research Associate III | Team |
Deborah Walwender | Research Associate | Team |
Lindsey Glenn | Manager, Translational Research | Team |
Complete people profiles for ReAlta Life Sciences
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of ReAlta Life Sciences
3 dated milestones of ReAlta Life Sciences across 8 years, from founding to its latest funding, stage changes and deals.
- Founded ReAlta Life Sciences is founded.
- Funding First funding round of $14.0M.
- Funding Latest funding round, Series C, of $40.0M.
Competitors of ReAlta Life Sciences
ReAlta Life Sciences has 3 listed competitors in our database, 3 of them funded. They include Moderna, BridgeBio and Spark Therapeutics.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| modernatx.com | 2010 | Cambridge, United States | $2.78B | 1,312 | mRNA-based therapeutics for diseases including cancer and infections are developed. | |
| bridgebio.com | 2015 | Palo Alto, United States | $434.2M | Therapeutics for genetic diseases are developed through targeted interventions. | ||
| sparktx.com | 2013 | Philadelphia, United States | $82.8M | 822 | Gene therapies for rare diseases including retinal dystrophies are developed. |
Detailed competitors of ReAlta Life Sciences
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of ReAlta Life Sciences
The website of ReAlta Life Sciences (realtalifesciences.com) receives about 1.7K visits a month.
- Monthly visits1.7K
▼ 8.5% vs previous month
Websites whose visitors overlap most with ReAlta Life Sciences. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| gc-tx.com | 100% | 4.6K | #3,942,181 | View details |
Top companies in Rare Diseases
3 companies that operate in the same segment as ReAlta Life Sciences (Rare Diseases) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Gene therapies for rare diseases including retinal dystrophies are developed. | 2013 | Philadelphia, Pennsylvania, United States | USD 82.8 M | USD 64.73 M | 822 | |
Therapeutics for genetic diseases are developed through targeted interventions. | 2015 | Palo Alto, California, United States | USD 434.2 M | USD 502.08 M | 730 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Realta Life Sciences
Complete news archive for ReAlta Life Sciences
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about ReAlta Life Sciences
ReAlta Life Sciences was founded in 2018 and raised its 1st funding round 2 years after it was founded.
ReAlta Life Sciences is headquartered in Norfolk, United States. It is registered at Norfolk, Virginia, United States.
Ulrich Thienel is the CEO of ReAlta Life Sciences, as recorded in our data.
ReAlta Life Sciences is a funded company, having raised a total of $121.5M across 5 funding rounds to date. The company's 1st funding round was a Series A of $14M, raised on Apr 2020.
ReAlta Life Sciences has 19 employees.
ReAlta Life Sciences, a clinical-stage company, is dedicated to addressing rare diseases through innovative drug development. The company has created a novel class of drugs utilizing the EPICC platform, which offers dual-targeting therapeutic capabilities to rebalance complement and inflammatory processes. Research and development initiatives are centered on acute inflammatory and rare diseases such as Hypoxic Ischemic Encephalopathy, Acute Exacerbations of COPD, Graft-versus-Host Disease, and Platelet Refractoriness. Solutions are developed to modify disease progression by moderating robust components of humoral and cellular inflammatory responses across various therapeutic areas.
ReAlta Life Sciences's top competitors include Moderna, Spark Therapeutics and BridgeBio.
ReAlta Life Sciences offers RLS-0071 (pegtarazimod) and EPICC Platform.
ReAlta Life Sciences has 1 investor. Key investors include Marathon Pharma.
ReAlta Life Sciences operates through Realta Life Sciences, Inc..